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Abstract
With the uptake of targeted therapies, instead of the “one-fits-all” approach, modern ran-
domized clinical trials (RCTs) often aim to develop treatments that target a subgroup of pa-
tients. Motivated by analyzing the Age-Related Eye Disease Study (AREDS) data, a large RCT
to study the efficacy of nutritional supplements in delaying the progression of an eye disease,
age-related macular degeneration (AMD), we develop a simultaneous inference procedure to
identify and infer subgroups with differential treatment efficacy in RCTs with survival outcome.
Specifically, we formulate the multiple testing problem through contrasts and construct their
simultaneous confidence intervals, which control both within- and across- marker multiplicity
appropriately. Realistic simulations are conducted using real genotype data to evaluate the
method performance under various scenarios. The method is then applied to AREDS to assess
the efficacy of antioxidants and zinc combination in delaying AMD progression. Multiple gene
regions including ESRRB-VASH1 on chromosome 14 have been identified with subgroups show-
ing differential efficacy. We further validate our findings in an independent subsequent RCT,
AREDS2, by discovering consistent differential treatment responses in the targeted and non-
targeted subgroups been identified from AREDS. This simultaneous inference approach provides
a step forward to confidently identify and infer subgroups in modern drug development.
Keywords: AMD progression, CE4, Cross-talk plot, Ratio of quantile survival, Subgroup identifi-
cation
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1. INTRODUCTION
With rapid advances in the understanding of human diseases, the paradigm of medicine shifts
from “one-fits-all to “targeted therapies or “precision medicine”. One aspect of precision medicine
research is to develop new therapies that target a subgroup of patients. The subgroups are usually
defined by “markers”, where the markers could be genotype information (such as mutation of a
certain gene), expression level of certain protein(s), disease severity or any biologically plausible
factors. For example, the KRAS status of patients with metastatic colorectal cancer is associated
with the progression free survival when treated by panitumumab monotherapy (Amado et al.,
2008), and the vemurafenib (Zelboraf) was approved for treating the BRAF -mutated metastatic
melanoma (Bollag et al., 2012). For another example, multiple genetic variations including FCER2
have been reported to be associated with the drug response among asthma patients using inhaled
corticosteroids (Garca-Menaya et al., 2019).
The drug development process typically involves comparing a new treatment (Rx) with a control
(C, such as a standard-of-care) through randomized clinical trials (RCTs), and treatment efficacy
is the “relative” effect between Rx and C. Finding the subgroups of patients that exhibit enhanced
treatment efficacy is a problem at the heart of modern drug development. To confidently identify
subgroups, it is often necessary to infer treatment efficacy in each group and some combination
of groups. For example, for a single nucleotide polymorphism (SNP) that separates patients into
three groups (denoted by AA, Aa and aa), one may have to decide whether the new treatment
should target a single group (e.g., aa) or a combination of groups (e.g., {Aa, aa}). In this case,
the treatment efficacy in both single genetic groups and their combinations need to be assessed.
As shown by Lin et al. (2019), when population is a mixture of subgroups with heterogeneous
efficacy, the efficacy measure needs to respect the logic relationship among subgroups and their
combinations. Take the SNP case as an example, if the treatment efficacy for Aa is x, and for aa is
y, then the efficacy for {Aa, aa} should be within [x, y] (assuming x ≤ y). This may sound trivial.
However, several commonly used efficacy measures such as the hazard ratio (for time-to-event data)
and the odds ratio (for binary data) do not satisfy this relationship (Ding et al., 2016; Lin et al.,
2019). Note that this logic-respecting is a property of an efficacy measure, not a property of the
type of data that quantifies the outcome, nor a statistical model for analyzing such data.
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Our research is highly motivated from analyzing the Age-Related Eye Disease Study (AREDS)
data, a RCT to study the risk factors for the age-related macular degeneration (AMD) and assess
the effect of micronutrients on delaying the progression to late AMD (Age-Related Eye Disease
Study Research Group, 1999). AMD is a polygenic and progressive neurodegenerative disease,
which is a leading cause of blindness in elderly. Patients can progress to one or both forms of late-
AMD – central geographic atrophy (GA) and choroidal neovascularization (CNV). The AREDS
study collected DNA samples of consenting participants and performed genome-wide genotyping
(Fritsche et al., 2016). Many genetic studies have shown that the development or the progression
of AMD is associated with various genetic risk factors (Seddon et al., 2007; Fritsche et al., 2016;
Yan et al., 2018; Sun and Ding, 2019). Specifically, in two recent genomewide association studies
for AMD progression using the AREDS data (Yan et al., 2018; Sun and Ding, 2019), where time-
to-late-AMD is the outcome, multiple variants from ARMS2-HTRA1 and CFH gene regions have
been discovered to be associated with AMD progression. Besides association analyses where no
treatment is involved, multiple research groups also investigated whether variants from these two
gene regions are associated with differential treatment responses. A recent review article by Cascella
et al. (2018) summarized the controversial findings. Research groups such as Klein et al. (2008)
and Seddon et al. (2016) reported that genetic variants from CFH and ARMS2 regions were found
to be associated with differential responses to the antioxidants plus zinc treatment. However, the
AREDS investigators reported no significant associations between CFH and ARMS2 regions and
the nutritional supplements, when multiplicity adjustment has been taken into account . To fully
understand the effects of those nutritional supplements on AMD progression and to infer whether
there are genetic subgroups with enhanced treatment efficacy, a rigorous statistical procedure that
can simultaneously identify and infer subgroups for time-to-event outcome is required.
There are existing methods for detecting heterogeneous treatment effects across groups for
time-to-event outcome. One simple but broadly used method is to test the treatment-by-marker
interaction in the Cox Proportional Hazards (CoxPH) model (Cox, 1972). However, this method
cannot provide which group to target directly, nor can it provide inference on subgroup-specific
efficacy. The second type of approach focuses on testing the existence of a subgroup (with an
enhanced treatment effect) using either a logistic-Cox model for the response in each subgroup and
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the latent subgroup membership (Wu et al., 2016) or a new CoxPH model including a nonparametric
component for the covariate in the control group and a subgroup-treatment-interaction effect defined
by a change plane (Kang et al., 2017). Similar to the interaction test, additional steps are needed
to provide inference in the targeted and non-targeted group. The third common approach utilizes
tree-based regression models, including RECursive Partition (Ciampi et al., 1995; Negassa et al.,
2005), interaction trees (Su et al., 2008), SIDES (Lipkovich et al., 2011), GUIDE (Loh et al.,
2015) and etc. One appealing feature of using these methods is that it can provide the tree
structure which incorporates multiple covariates at the same time. However, none of these methods
provides inference for treatment efficacy in both targeted group and non-targeted group, and some
approaches use illogical efficacy measures. The targeted treatment development process involves
the co-development of a drug compound and a companion diagnostic tool that identifies the suitable
subgroup of patients for the drug to target. Therefore, the subgroup has to be “simple” (usually
defined by one or two biomarkers) for clinical and regulatory feasibility. In this article, we develop a
multiple-testing-based approach which aims to simultaneous identify and infer “simple” subgroups
with enhanced treatment efficacy.
The article is organized as follows. Section 2 introduces the logic-respecting efficacy measure for
time-to-event outcomes that we choose to use and its associated properties, and with that efficacy
measure how we formulate the contrasts to identify subgroups and adjust for the multiplicity.
Section 3 presents simulations to show finite sample performance of the proposed method and uses
realistic simulations to summarize practical rules for the use of the method. Then we apply our
method on the Age-related Eye Disease Study (AREDS) data and present our findings in Section
4. Finally, we discuss and conclude in Section 5.
2. METHODS
In this article, we deal with ordinal categorical markers which separate the population into a few
groups (e.g., three groups by a SNP, or four groups by the immunohistochemistry test). Below we
use the scenario of “three-category” marker (M = 0, 1, 2) to illustrate our method. Brief discussions
are provided in Section 5 regarding how to generalize the method to handle markers with more
categories or continuous markers.
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2.1 Issues with hazard ratio
First, we demonstrate why the commonly used HR is not a suitable efficacy measure when the
population is a mixture of subgroups. Let HR0,HR1,HR2 denote the hazard ratio for each subgroup
defined by M , and let HR01 denote the HR for the {M = 0, 1} combined. HR is not logic-respecting
in the sense that even if both HR0 and HR1 are constant, the combined population typically does
not have a constant HR. In fact, the HR of the mixture population is usually a complex function
of time, with values at some time points outside of [HR0,HR1]. This is because HR01 can not
be expressed as a weighted combination of HR0 and HR1. The combination can only be made on
density or cumulative density functions, not on the hazard ratio scale. For example, we can generate
data from a Weibull distribution where HR0 = HR1 = exp(−0.2) = 0.82, with an equal prevalence
of the two subgroups. However, the true HR01 is a smooth function of time and goes above 0.82
when t is large. In this case, it is possible that another subpopulation has HR2 = 0.84 and then at
some large time (e.g., t > 1.1), HR0 = HR1(= 0.82) < HR2(= 0.84) < HR01(= 0.85) < 1, meaning
{M = 2} exhibits more efficacy than {M = 0, 1} combined, but does not exhibit more efficacy
than either {M = 0} or {M = 1}. Thus using HR as the efficacy measure can lead to paradoxical
findings in patient targeting.
2.2 Ratio of quantile survival times and its property
Realizing that HR is not suitable to use in the presence of mixture population, a different measure
needs to be considered. Ding et al. (2016) demonstrated that the ratio or difference of mean or
median survival times (between Rx and C) is logic-respecting by guaranteeing µ0 ≤ µ01 ≤ µ1,
where µ denotes the efficacy measure. In this manuscript, we choose ratio of quantile survival
times as our efficacy measure and demonstrate that it has a unique property under the CoxPH
model that we consider. Assume the time-to-event data fit the following model:
h(t|Trt,M,X) = h0(t){β1I(Trt = 1) + β2I(M = 1) + β3I(M = 2) +
β4I(Trt = 1)× I(M = 1) + β5I(Trt = 1)× I(M = 2) + β6X}, (1)
where Trt = 0 (C) or 1 (Rx) is the treatment assignment, M = 0, 1, or 2 is the marker we
consider for testing, and h0(t) = h(t|C,M = 0,X = 0) is the hazard function for the {M = 0}
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group receiving C, with additional covariates set to 0. Further we assume that the baseline survival
function is from a Weibull distribution with scale λ and shape k, which corresponds to h0(t) =
h(t|C,M = 0,X = 0) = ktk−1
λk
. Denote by νTrtM,τ the corresponding quantile (τ) survival time in
each marker-by-treatment group. Let θl = e
βl , l = 1, . . . , 5 and θ6 = e
β6X with βs from (1), then by
setting the survival function for each group equal to τ , the corresponding survival and their ratios
can be directly calculated as follows:
νRx0,τ = λ(
log τ
θ1θ6
)
1
k , νC0,τ = λ(
log τ
θ6
)
1
k , r0 =
νRx0,τ
νC0,τ
= (
1
θ1
)
1
k ,
νRx1,τ = λ(
log τ
θ1θ2θ4θ6
)
1
k , νC1,τ = λ(
log τ
θ2θ6
)
1
k , r1 =
νRx1,τ
νC1,τ
= (
1
θ1θ4
)
1
k ,
νRx2,τ = λ(
log τ
θ1θ3θ5θ6
)
1
k , νC2,τ = λ(
log τ
θ3θ6
)
1
k , r2 =
νRx2,τ
νC2,τ
= (
1
θ1θ5
)
1
k .
It can be seen that the quantile survival time for each group depends on the baseline character-
istics (θ6), but the ratio does not. We name it as the covariate invariant property. This property
is unique to this efficacy measure, which is attractive as it makes the comparison (between Rx and
C) simple. Further it can be shown that this property also holds in the combined groups. For
example, suppose we are interested in the ratio of quantile survival times in the mixture population
of {M = 0, 1} (denoted as rτ01). We can calculate rτ01 from its definition, rτ01 =
νRx01,τ
νC01,τ
, where νRx01,τ
and νC01,τ can be obtained by solving the following equations,
t = νRx01,τ : p0e
{−θ1θ6( tλ )k} + (1− p0)e{−θ1θ2θ4θ6( tλ )k} = τ,
t = νC01,τ : p0e
{−θ6( tλ )k} + (1− p0)e{−θ2θ6( tλ )k} = τ, (2)
with p0 representing the prevalence of M = 0 in the combined population {0, 1}. By combining
the two groups at the probability level, this calculation follows the subgroup mixable estimation
(SME) principle (Ding et al., 2016). Let xRx01,τ = θ6(
νRx01,τ
λ )
k and xC01,τ = θ6(
νC01,τ
λ )
k, then we have
rτ01 =
νRx01,τ
νC01,τ
= (
xRx01,τ
xC01,τ
)
1
k . Since the solutions for xRx01,τ and x
C
01,τ from equation (2) are free of θ6, we
also have the covariate-invariant property for rτ01.
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2.3 Confident Effect 4 contrasts (CE4) for ratio of quantile survival times
In targeted therapy development, researchers are interested in (1) whether there exists a subgroup
with enhanced treatment efficacy and (2) the treatment efficacy in both targeted and non-targeted
subgroups (for appropriate drug labeling) (Lin et al., 2019). To answer both questions simultane-
ously, we propose to use contrasts to compare efficacy between different subgroups and combination
of subgroups. Under the same scenario with three groups defined by a marker (M = 0, 1, or 2),
in order to get a complete ordering of the treatment efficacy in all possible groups, we propose the
following four contrasts:
log κ(1,2):0 = log(
r12
r0
) = log r12 − log r0, log κ1:0 = log(r1
r0
) = log r1 − log r0,
log κ2:(0,1) = log(
r2
r01
) = log r2 − log r01, log κ2:1 = log(r2
r1
) = log r2 − log r1. (3)
We drop τ in the notation as τ is pre-specified. Moreover, these contrasts are built on the log
scale of the efficacy measure since previous experience demonstrates the normality approximation
seems to work better on the log scale (as compared to the original scale) (Ding et al., 2016). In
fact these four contrasts are analogous to the contrasts proposed in Ding et al. (2018) where the
efficacy in their case is measured by a continuous outcome. As pointed by Ding et al. (2018), they
are equivalent to testing the following eight one-sided null hypotheses where each one is to test an
inequality against its complement (i.e., H0 : κ(1,2):0 ≤ 1 vs Ha : κ(1,2):0 > 1) rather than testing a
zero null (such as H0 : κ(1,2):0 = 1).
H≤(1,2):0 : κ(1,2):0 ≤ 1, H≤(0,1):2 : κ(0,1):2 ≤ 1, H≤1:0 : κ1:0 ≤ 1, H≤1:2 : κ1:2 ≤ 1
H≤2:(0,1) : κ2:(0,1) ≤ 1, H≤0:(1,2) : κ0:(1,2) ≤ 1, H≤2:1 : κ2:1 ≤ 1, H≤0:1 : κ0:1 ≤ 1.
From these eight one-sided tests, we are able to tell which subgroup or combination of subgroups
exhibits a differential efficacy than its complementary group.
We propose to use simultaneous confidence intervals on these four contrasts so that we can
identify differential subgroup(s) and infer their efficacy simultaneously. Note that level 100(1−α)%
simultaneous confidence intervals for those contrasts effectively form a level-α interaction test: reject
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the null hypothesis of no interaction between Treatment effect (Trt) and marker group (M) if at
least one of the confidence intervals does not contain zero. Moreover, this formulation of assessing
“interaction” effect is advantageous toward patient targeting as it allows decision-making based
on clinically meaningful differences (reflected from confidence intervals on efficacy comparisons)
instead of a mere statistical significance (such as the p-value from the typical interaction test). To
estimate the four contrasts from (3) under our model (1), we propose the following three steps and
name this approach as “CE4-Weibull”:
- Step 1. Estimate all the parameters in the Weibull model (e.g., λ, k, βl, l = 1, . . . , 6).
- Step 2. Estimate the quantile survival times νTrt0,τ , ν
Trt
1,τ , ν
Trt
2,τ , ν
Trt
01,τ , ν
Trt
12,τ , Trt = Rx or C, based
on the parameter estimates obtained in Step 1 and their associated variance covariance matrix.
- Step 3. Estimate r0, r1, r2, r01 and r12 and their variance covariance using estimators obtained
from Step 2 and then calculate the four contrasts CE4.
The estimated variance covariance matrices in Step 2 and Step 3 can be obtained using the Delta
method. Note that in Step 2, the Delta method for implicitly defined random variables (Benichou
and Gail, 1989) needs to be applied since the quantile survival times in the combined groups (e.g.,
{0, 1} and {1, 2}) are not explicitly defined, but rather from solving equations like (2).
The estimated CE4 will asymptotically follow a multivariate normal distribution and the simul-
taneous confidence intervals can be then derived as follows. We compute the quantile q such that
the four simultaneous confidence intervals
log(κˆg)− qsˆgg < log(κg) < log(κˆg) + qsˆgg, g = {(1, 2) : 0, 2 : (0, 1), 1 : 0, 2 : 1}
have a coverage probability 1− α, that is, the joint probability
Pr
( | ˆlog(κg)− log(κg)|
sˆgg
< q, g = {(1, 2) : 0, 2 : (0, 1), 1 : 0, 2 : 1}
)
= 1− α,
where sˆ2gg is the variance estimator for log(κˆg). The R package {mvtnorm} can be used to obtain
this q value. Then the p-value (from testing the eight one-sided null hypotheses simultaneously) can
be obtained from the multivariate normal distribution as well, which corresponds to the smallest
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p-values from the four single contrasts. If any of the four contrasts does not cover 0, it suggests
that there exists subgroup(s) with differential treatment efficacy.
2.4 Multiplicity adjustment across biomarkers
In targeted treatment development, typically a large collection of markers need to be tested in
order to identify subgroups. Therefore, there are two families of inferences need to be considered:
within a marker and across markers. Specifically, strong control of familywise error rate (FWER)
for inference within a marker is desired, since the consequence of an incorrect inference may target
a wrong subgroup, which is serious. The simultaneous confidence intervals obtained from our CE4-
Weibull method appropriately controls the within-marker FWER. While the error rate for inference
across multiple markers can be controlled less stringently, since multiple candidate markers can be
identified for tailoring (which may indicate largely overlapped subgroups to target), and therefore
the perfamily error rate seems acceptable.
Suppose there are a total of K markers to be tested. Denote by Vk the number of confidence
intervals that fail to cover the true values for the kth marker. Then the FWER for the kth SNP
is αk = P{Vk > 0} = E[I{Vk>0}]. For inference across SNPs, denote by V∗ the number of markers
that have at least one of its confidence intervals failing to cover its true value. Then the perfamily
error rate is E[V∗] = E
[
K∑
k=1
I{Vk>0}
]
=
K∑
k=1
P{Vk > 0} =
K∑
k=1
αk. We suggest to use the simple
additive adjustment as proposed by Ding et al. (2018), of which by setting the desired perfamily
error rate as m (a pre-specified positive integer), the familywise αk for each marker is then set to
be mK (same across all markers).
When SNPs are the biomarkers to define subgroups, the screening process seems similar to a
genome-wide association study (GWAS). However, our proposal controls for perfamily error rate
instead of the commonly used false discovery rate (FDR). In GWAS, it is plausible biologically that
the vast majority of the SNPs are not associated with the specific disease. However, when treat-
ments are involved, the biological processes become more complex, and zero-nulls of no-difference
(e.g., phrased as H0 : κ(1,2):0 = 1) are statistically false, which was first observed in the setting of
Ding et al. (2018), where the treatment efficacy was simulated based on a single causal SNP with
no random error being added. It was found that practically all other SNPs would appear “associ-
ated” with the outcome (as sample size reaches infinity) when analyzed in a SNP-by-SNP fashion.
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The reason is that most SNPs are not “orthogonal” to each other, and thus any SNP will appear
somewhat associated with treatment outcome as long as the distribution for proportions of being
{AA,Aa, aa} in this SNP and the causal SNP are not independent, which is most of the cases.
When there are no zero-nulls statistically, the “false” discovery seems lame, and the perfamily
rate is preferred by providing more meaningful candidates. We have more discussions about the
zero-null issue in Section 3.
3. REALISTIC SIMULATIONS
3.1 Single SNP simulations
We use SNPs as the biomarkers in all simulation studies. First, simulation studies based on a sin-
gle SNP were conducted to investigate the finite sample performance of the proposed CE4-Weibull
method. We considered three scenarios: (1) No SNP effect, i.e., Rx is not efficacious for any
genotype group; (2) The allele a has a dominant beneficial effect on Rx ; (3) The allele a has a
recessive beneficial effect on Rx. The SNP was simulated from a multinomial distribution with
(Paa = 0.16, PAa = 0.48, PAA = 0.36) (corresponding to minor allele frequency (MAF) of 0.4).
Survival times were simulated from model (1) with scale λ = 2 and shape k = 1.25. The param-
eters (β1, β2, β3, β4, β5, β6) were set to be (0,−0.8,−0.8, 0, 0, 0), (0,−0.8,−0.8,−0.6,−0.6, 0) and
(0,−0.8,−0.8, 0,−0.6, 0) for the three scenarios respectively. The censoring times were generated
from an independent uniform distribution U(a, b) with a and b chosen to yield 20% and 50% censor-
ing rates. We chose the quantile τ as 0.5 which corresponds to the median survival. The true values
of the CE4 contrasts (κ(1,2):0, κ2:(0,1), κ1:0, κ2:1) using the ratio of median survival as the efficacy
measure for each scenario are: (1) (1, 1, 1, 1), (2) (1.62, 1.27, 1.62, 1), and (3) (1.12, 1.62, 1, 1.62).
We ran 1000 simulations for each scenario, with sample size 500 for each treatment arm and the
results are summarized in Figure 1. Across all the scenarios, the biases of the CE4 estimates are
minimal and the coverage probabilities for the simultaneous confidence intervals (SCP) are all close
to 95%. Larger variations are observed in biases of κˆ2:(0,1) and κˆ2:1, especially under scenario 3.
This is because under the recessive effect setting, Rx is only efficacious in {aa} patients, which is a
small proportion of the total population (16%). Therefore, the contrasts involving the comparison
between aa and other group (or the combination of other groups) have larger variances.
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Figure 1: Finite sample performance of CE4-Weibull: bar plots of the biases of CE4 estimators.
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3.2 Realistic simulations
To understand the performance of the proposed CE4-Weibull method in the real genetic setting
with a large number of SNPs, we used the chromosome-wide data from AREDS. Among those
(> 2700) participants who had DNA collected and genotyped, we randomly selected 1000 Cau-
casian participants and randomly “assigned” them in a 1:1 ratio to the new treatment Rx and a
standard care C. Since AMD is known as a polygenic disorder and many studies have discovered
or confirmed genetic risk variants associated with AMD, in this realistic simulation, we selected
a variant rs2284665 from the well-known AMD risk gene region ARMS2 on Chromosome 10 as
the causal SNP, and assumed the minor allele of this variant has a dominant beneficial effect
on Rx. We kept the three genotype groups (defined by the causal SNP) balanced between Rx
and C. Similar as in the single SNP simulations, the progression times were simulated from the
Weibull model with λ = 2 and k = 1.25. The parameters for (β1, β2, β3, β4, β5, β6) were set to
be (0,−0.5,−0.5,−0.8,−0.8, 0), corresponding to (κ(1,2):0, κ2:(0,1), κ1:0, κ2:1) = (1.90, 1.51, 1.90, 1).
The censoring rate was set to be 25%. Therefore, the SNP data were real (from real subjects) and
the progression times and SNP effects were simulated.
We analyzed chromosome 10 using our CE4-Weibull model and filtered the SNPs with less
than three patients in each genotype group within each treatment arm, which resulted in a total
of 268,053 SNPs. We set m = 10, allowing on average 10 out of ∼ 270,000 SNPs with at least
one confidence interval failing to cover its true value, which is equivalent to setting the αK level at
3.73× 10−5 (= mK = 10268,053). A total of 37 SNPs were identified by CE4-Weibull. Among those 37
SNPs, 30 of them are from the ARMS2-HTRA1 region, including the causal SNP. Other seven SNPs
belong to six different gene regions, which are distance away from the causal gene region. Figure
2A plotted the positions of these SNPs relative to the causal SNP, with y-axis (− log10(p.CE4))
showing the significance level of each SNP. Figure 2B plotted MaxEff vs − log10(p.CE4), where
MaxEff (maximal effect) is defined as the maximum absolute value among the estimated CE4
contrasts that do not cover zero. The causal SNP has the smallest p-value (= 8.52 × 10−10) and
with MaxEff of 2.20. Note that some top SNPs have very large MaxEff values. For example, SNP
rs10857454 from the C10orf128-C10orf71-AS1 region has the largest MaxEff of 29.7, while its p-
value is relatively large (= 3.21 × 10−6, close to the threshold). We caution against the situation
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when a huge effect size is seen, since such a huge effect for treatment efficacy is clinically unlikely.
For this specific SNP, it is not surprising to see the corresponding confidence interval for κ2:(0,1) is
very wide and the effective patient population only consists 1.5% of the total population.
To further investigate the relationship between the top SNPs and the causal SNP, we proposed
a novel SNP cross-talk plot. It is based on a ternary diagram using barycentric coordinates to
display the proportion of three variables that sum to one. Specifically, we projected the percentages
of the AA, Aa, and aa categories of the causal SNP rs2284665 in each of these categories of a given
top SNP onto the triangular diagram, and connect the points with lines. If the SNP is highly
correlated with the causal SNP in terms of the distribution of AA, Aa, and aa, the percentages
will be close to (1,0,0), (0,1,0) and (0,0,1), and thus the connected line segments will be long and
lie closely to the two edges of the triangle. Otherwise, the three dots will be close to each other
to give a short angle. For example, in Figure 2C, the causal SNP has a perfect match in terms
of the percentages with itself so the three points are the vertexes of the triangle, which makes the
connected line segment coincide with the edges AA − Aa and Aa − aa (denoted by the dashed
lines). From the plot, all 30 SNPs from ARMS2-HTRA1 region are highly correlated with the
causal SNP, indicated by the long red line segments, which explains why they have been identified
by CE4-Weibull. For the 7 SNPs from other regions, their line segments are all short, indicating
they might have been identified due to randomness. Then we repeated this chromosome-wide
realistic simulation for 100 times.
3.3 Results from 100 realistic simulations
In these 100 repeated runs, the SNP data are all the same but the progression times and censoring
times are different due to randomness from the model. By setting m = 10, on average there are
61 SNPs identified per run with a total of 3292 SNPs being picked at least once. The causal SNP
were picked 90 out of 100 times and the distribution of the ranks is shown in the stem-and-leaf plot
(upper panel in Figure 3). Note that 84 out of 90 times the rank of the causal SNP was among top
30 and 52 times it was among top 10, indicating that our CE4-Weibull is robust in identifying the
true causal SNP. The lower panel in Figure 3 summarizes all the identified SNPs from all 100 runs
in terms of their relative position to the causal SNP and their frequencies of being picked up. We
found that 98.9% of the 3292 SNPs were only picked less than 5 times, which are highly likely due
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Figure 2: 37 identified SNPs from one chromosome-wide realistic simulation. A: -log10(p.CE4) vs.
relative position to the causal SNP; B: the maximum effect among CE4 vs. -log10(p.CE4); the 4 is
the causal SNP rs2284665 and ‘+’s are the SNPs that from the same rigion with the causal SNP.
The rests are from other gene regions; C: SNP cross-talk plot.
15
to randomness. While for SNPs close to the causal SNP and located in the same ARMS2-HTRA1
gene region, the probability of being selected is much higher, among which 27 SNPs were identified
for more than 80% of the times. From this repeated chromosome-wide simulations, we confirmed
that there are possibilities that some SNPs are picked by random error but the true causal SNP
and its surrounding SNPs can be identified with very high probabilities by CE4-Weibull. Moreover,
due to the existence of linkage disequilibrium among SNPs, it is very unlikely that an isolated SNP
will be the true causal SNP.
Based on the observations from our realistic simulations, we recommend the following rules
to guide the selection of “candidate” SNPs from those identified by CE4-Weibull. (1) There are
multiple SNPs (e.g.,≥ 4) being picked from the same gene region; (2) The MaxEff should not be
unrealistically large; and (3) The targeted group should be a reasonable proportion (not too small
or large, e.g., 5%− 95%) of the total population.
4. APPLICATION TO AREDS DATA
4.1 Background
AREDS is a large multi-center RCT sponsored by the National Eye Institute to evaluate the effect
of antioxidants and/or zinc on delaying the progression of AMD (Age-Related Eye Disease Study
Research Group, 1999). The original study includes four treatment arms: placebo, antioxidants,
zinc and the combination of antioxidants and zinc, where the last treatment then becomes the
“AREDS formula” dietary supplements which are now available in various drug stores. However, the
treatment effects of the non-placebo arms on delaying the late AMD progression are not statistically
significant (Ding et al., 2017). Among the four arms, we specifically investigated participants in the
placebo arm (C) and the combination of antioxidants and zinc treatment arm (Rx), which included
1,170 Caucasian participants with both eyes free of advanced AMD progression when entering the
study. The outcome is the time-to-late-AMD from the first progressed eye, where late-AMD is
defined as the severity score reaches 9 or above (9=GA, 10=central GA, 11=CNV, 12=central
GA and CNV). As shown in Table 1, age, sex and smoking status do not differ between the two
treatment arms. However, the baseline AMD severity score is significantly higher among patients
who were randomized to the Rx group, as compared to patients who were randomized to placebo
16
Figure 3: Upper: stem-and-Leaf plot for the distribution of the ranks of the Causal SNP; Lower:
present frequency of the identified SNPs in 100 simulations
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(4.0 ± 2.2 vs 2.6 ± 2.1). This is as expected and is due to the randomization design: patients
free of AMD at baseline can only be randomized to the placebo or antioxidants arms, but not the
combination arm, and thus the baseline severity score needs to be adjusted in the analysis. The
overall censoring rate is about 75%, so we used τ = 0.75 as our quantile.
4.2 CE4-Weibull on AREDS
We first evaluated the treatment effect of “AREDS formula” on time-to-progression in the overall
population using a Weibull regression model, adjusting for the known risk factors including age,
smoking status, and baseline severity score. The estimated HR between Rx and C is 1.15 with
p = 0.26, and the ratio of 75th quantile progression-free time for Rx and C is 0.91 with p = 0.12. It
suggests that the combination of antioxidants and zinc does not seem to be effective in slowing down
the disease progression in the overall population, which is consistent with previous findings (Ding
et al., 2017). Then we applied CE4-Weibull method to analyze all common variants (i.e., MAF ≥
0.05) across 22 autosomal chromosomes, resulting in a total of 3,837,556 SNPs. Similarly, baseline
age, smoking status and severity score were adjusted. The upper panel of Figure 4 presents the
Manhattan plot of this genome-wide CE4-Weibull analysis. By setting m = 10, a total of 46 SNPs
meet the significance threshold of 2.61 × 10−6(= m/K). These SNPs are from nine gene regions
on seven chromosomes. Following the recommendation rule we proposed in Section 3.3, there are
three gene regions each with at least four SNPs meeting the p-value threshold and they are labeled
in the Manhattan plot: CHST3-SPOCK2 on CHR 10 (4 SNPs), ESRRB-VASH1 on CHR 14 (30
SNPs), and C19orf44-CALR3 on CHR 19 (6 SNPs). We examined the correlation between all 46
identified SNPs using the cross-talk plot and presented the result in the lower panel of Figure 4.
We picked rs147106198 (from ESRRB-VASH1 region on CHR14), which has the smallest p-value
(= 7.00×10−8) as the reference SNP. It can be seen that the other 29 SNPs from the same ESRRB-
VASH1 region are highly correlated with the top SNP rs147106198, indicated by the long edges
of the red segments. The other two gene regions, CHST3-SPOCK2 and C19orf44-CALR3 are not
highly correlated with the ESRRB-VASH1 region, although the multiple SNPs within each region
are highly dependent on each other (denoted by overlapped segments in green or blue color). In
this case, there may be more than one causal SNP that leads to the differential treatment effects.
We picked the top SNP (rs147106198 on CHR14) as our candidate marker for further discus-
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Table 1: Baseline characteristics of the AREDS data
Number of subjects
All
(n=1170)
Placebo
(n=754)
Antioxidants and Zinc
(n=416)
p-value*
Age 0.309
Mean (SD) 68.4 (4.9) 68.3 (4.8) 68.6 (4.9)
Median (Range) 68.2 (55.3-81.0) 68.0 (55.3-81.0) 68.7 (55.5-79.5)
Sex (n, %) 0.289
Female 655 (56.0) 413 (54.8) 242 (58.2)
Male 515 (44.0) 341 (45.2) 174 (41.8)
Smoking (n, %) 0.758
Never Smoked 571 (48.8) 371 (49.2) 200 (48.1)
Former/Current Smoker 599 (51.2) 383 (50.8) 216 (51.9)
Baseline AMD severity score <0.001
Mean (SD) 3.2 (2.2) 2.6 (2.2) 4.0 (2.1)
Median (Range) 2.0 (1.0-8.0) 1.0 (1.0-8.0) 4.0 (1.0-8.0)
Status (n, %) <0.001
Progressed 269 (23.0) 133 (17.6) 136 (32.7)
*p-value is based on two-sample t test or Pearson Chi-square test for continuous or categorical variables
sion. Figure 5 demonstrates the treatment effect profiles and simultaneous confidence intervals for
rs147106198, where the efficacy profile may suggest a dominant beneficial effect of a. The CE4
simultaneous confidence intervals confirm that the targeted group is {Aa,aa} combined since the
confidence intervals of κ(1,2):0 and κ1:0 are above the zero line. This targeted group consists about
52% of the total patients, a reasonably high proportion of the entire population. Moreover, the
estimated ratio of 75th quantile progression-free times in the targeted and non-targeted groups
(between Rx and C) can be obtained, which are 1.44 and 0.57 for {Aa,aa} and {AA}, respectively,
indicating that the combination of antioxidants and zinc treatment extends the progression time
for 44% compared to the placebo in the targeted group. The corresponding simultaneous 95%
confidence intervals for treatment efficacy (on the log scale) for the targeted and non-targeted pop-
ulation were also constructed and plotted in the right panel of Figure 5. Finally, the characteristics
of targeted and non-targeted population based on rs147106198 are summarized in Table 2. As
for the baseline characteristics and treatment assignment, the patients in the targeted group do
not differ from the patients in the non-targeted group, indicating that the enhanced benefit from
the treatment in the targeted population is plausibly due to the genetic difference rather than the
demographic or clinical differences.
To help elucidate the controversial findings regarding whether genetic polymorphisms of CFH
and ARMS2 alter the treatment efficacy of AREDS formula, we closely checked 6 SNPs from
19
Figure 4: Upper: Genome-wide CE4-Weibull analysis result; Lower: SNP cross-talk plot for 40
identified SNPs in relationship with the most top SNP rs147106198.
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Table 2: Characteristics of targeted and non-targeted populations
rs147106198: chr14, ESRRB-VASH1 region
Targeted Non-targeted p-value
# of subjects (n,%) 605 (51.7) 565 (48.3)
Treatment efficacy
νˆRx,0.75
νˆC,0.75
† (SE) 1.44 (1.01) 0.57 (1.01) 6.99× 10−8?
Age 0.560
Mean (SD) 68.5 (4.8) 68.4 (4.9)
Median (range) 68.2 (55.3-81.0) 68.2 (55.8-80.5)
Sex (n, %) 0.982
Female 338 (55.9) 317 (56.1)
Male 267 (44.1) 248 (43.9)
Smoking (n, %) 0.169
Never Smoked 283 (46.8) 288 (51.0)
Former/Current Smoker 322 (53.2) 277 (49.0)
Treatment (n, %) 0.510
Placebo 384 (63.5) 370 (65.5)
Antioxidant + Zinc 221 (36.5) 195 (34.5)
Baseline AMD severity score 0.487
Mean (SD) 3.1 (2.2) 3.2 (2.2)
Median (range) 2.0 (1.0-8.0) 3.0 (1.0-8.0)
†: νˆ denotes the estimated quantile progression time
?: p-value is from the corresponding CE4 contrast when simultaneous type I error is controlled, without adjusting for cross-SNP multiplicity
Figure 5: Top identified SNP from AREDS, rs147106198. Left: treatment profile using log of
the ratio of 75th quantile survivals; Middle: CE4 results by taking the difference between the log
ratio of 75th quantile progression time to late AMD in the presented contrasts; Right: estimated
treatment efficacy (log ratio of 75th quantile survivals) in targeted and non-targeted groups.
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Table 3: CE4 results of six selected SNPs from CFH and ARMS2-HTRA1 regions
Gene SNP p.CE4 rank.CE4
CFH
rs7522681 3.74× 10−4 3843
rs412852 9.49× 10−4 9021
rs1061170 1.22× 10−2 71651
rs3766405 0.38 1614412
ARMS2-HTRA1
rs11200647 7.75× 10−2 378198
rs10490924 0.77 3059694
these two regions and their results are presented in Table 3. Note that rs412852, rs1061170, and
rs3766405 from CFH and rs10490924 from ARMS2-HTRA1 have been previously investigated in
Seddon et al. (2016); Vavvas et al. (2018); Assel et al. (2018). We also reported the SNPs with the
smallest CE4-based p-value from each region, which are rs7522681 and rs11200647. None of the 6
SNPs meets the significance threshold of 2.61× 10−6, although 3 SNPs from CFH region meet the
nominal level of 0.05. We further investigated rs412852 from CFH and it seems our CE4-Weibull
result suggests the combination group {AA,Aa} exhibiting better treatment efficacy compared to
its complementary group {aa}, which is similar to the findings from Seddon et al. (2016) and Assel
et al. (2018). However, it is worthwhile to note that from our genomewide CE4 analysis, none
of these SNPs ranked top (Table 3). Therefore, with appropriate multiplicity adjustment, neither
CFH or ARMS2-HTRA1 region has SNPs showing significant association with treatment efficacy,
which is consistent with the conclusion indicated by Chew et al. (2015).
It should be noted that based on different SNPs, the suggested targeted population may vary. In
this example, if a top SNP from CHST3-SPOCK2 on CHR 10 is considered as the biomarker (e.g.,
rs1245576), the targeted population is about 65.8% of the total population, which overlaps with
the targeted population indicated by rs147106198 by 67.1%. Our CE4-Weibull method provides
reliable and interpretable candidate targeted populations for consideration, while the final decision
on which population to target involves many other considerations such as development of companion
diagnostics, labeling, marketing, and reimbursement.
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4.3 Validation on AREDS2
AREDS2 was another independent large multi-center RCT of AMD (Chew et al., 2012). It was
designed to evaluate the effect of refined AREDS formulations on AMD progression, as compared
to the original AREDS formulation. Participants of AREDS2 were more severe at baseline and
the follow-up time was only about half of the AREDS’s follow-up time. Four arms were in-
cluded: AREDS formulation, AREDS formulation plus Lutein/Zeaxanthin, AREDS formulation
plus DHA/EPA, and AREDS formulation plus Lutein/Zeaxanthin and DHA/EPA. Since there is
no real placebo arm in AREDS2, we cannot apply CE4-Weibull to identify subgroups with en-
hanced efficacy of AREDS formulation directly in AREDS2. Instead, we specifically investigated
the patient’s response to the same antioxidants and zinc combination treatment to check whether
we observe similar differential response patterns between the AREDS identified targeted and non-
targeted groups in AREDS2 as compared to AREDS. We used the same SNP rs147160198 to de-
termine whether a patient belongs to targeted {Aa,aa} group or non-targeted {AA} group in both
studies. Table 4 presents the patient characteristics within the targeted and non-targeted groups,
separately for AREDS and AREDS2. None of the baseline risk factors differs between targeted and
non-targeted populations in each study. Between the two studies, AREDS2 patients are older and
more severe and thus are anticipated to progress faster. Figure 6 compares the progression-free
Kaplan-Meier curves between the targeted and non-targeted groups within each study. In both
studies, the targeted population shows an obvious better progression-free profile than the non-
targeted population, with the log-rank test pvalue of 0.00011 and 0.013, respectively. Therefore,
we successfully validated our identified targeted group by SNP rs147160198 in AREDS2. We also
checked the subgroups indicated by reported SNPs from the CFH region, for example rs412852. In
AREDS, the two groups ({AA,Aa} vs aa) exhibit differential treatment response profiles (log-rank
p < 0.001). However, such differential response profiles were not observed in AREDS2. This further
emphasizes appropriate multiplicity adjustment is crucial for robust subgroup identification.
4.4 Data Availability
The phenotype and genotype data of AREDS and AREDS2 are available from the online repository
dbGap (accession: phs000001 : v3 : p1, and phs001039 : v1 : p1, respectively). The proposed
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Figure 6: Kaplan-Meier curves for targeted/non-targeted patients taking antioxidants and zinc
combination in AREDS and AREDS2, where the subgroup is defined by rs147106198.
method and its applications are implemented in R. The key functions can be obtained from GitHub
upon the acceptance of this manuscript.
5. CONCLUSION AND DISCUSSION
In this work, we develop a new statistical method to confidently identify and infer subgroups in
modern RCTs with time-to-event outcomes. Different from machine learning based approaches,
our CE4-Weibull approach, derived from the fundamental multiple testing principle, provides si-
multaneous confidence intervals on contrasts that directly compare the treatment efficacy between
subgroups or combination of subgroups. The contrasts are built upon a logic-respecting efficacy
measure, the ratio of quantile survival times (between Rx and C), which enjoys the unique covariate
invariant property in addition to its interpretation-friendly feature.
Our CE4-Weibull adjusts for multiplicity both within and across the markers. It rigorously
combines two error rate controls, familywise error rate control within each marker, and per family
error rate control across the markers. Such error control is appropriate in a drug development pro-
cess, as it allows flexibility in the exploration of multiple candidate markers, while being confident
in the patient subgroup to target from any selected marker(s). Such a novel and rigorous multiplic-
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ity adjustment contributes to the reduction in the so-called “reproducibility crisis” in which many
discoveries in markers or effective subgroups turn out to be false positive findings.
From our realistic simulation studies where the SNP data are taken from true individuals, we
recommend practically useful rules for identifying “candidate” markers. Finally, we successfully
applied our method on AREDS data to identify subgroups that exhibit enhanced treatment effi-
cacy with combination of antioxidant supplements and zinc in delaying AMD progression. After
conducting the genomewide analysis using our CE4-Weibull method, three gene regions were dis-
covered to suggest subgroups with significantly enhanced efficacy: CHST3-SPOCK2 on CHR 10,
ESRRB-VASH1 on CHR 14, and C19orf44-CALR3 on CHR 19. We further validated the sub-
groups defined by the top SNP rs147106198 from ESRRB-VASH1 region using the data from an
independent AREDS2 study. SanGiovanni et al. (2013) found that the estrogen related receptor
beta (ESRRB) was (weakly) associated with CNV AMD. Wakusawa et al. (2008) first demonstrated
the angiogenesis modulation of VASH is involved in the pathological process of AMD. Later Zeng
et al. (2012) inferred that the treatment with AREDS formulation is likely to affect both angiogen-
esis and endothelial-macrophage interactions. Thus our findings provide new perspectives on the
differential treatment efficacy, suggested by genetic polymorphisms for delaying AMD progression.
Although we use the SNP testing scenario to demonstrate our method, the key elements of
the method apply to broader scenarios with all kinds of markers to consider. When the marker
separates the patient population into more groups (> 3), additional contrasts need to be considered
to obtain the complete ordering of the treatment efficacy, which will then be used to identify the
subgroups. The current version of our method only handles discrete markers and more work is
required to generalize it for continuous markers. In doing that, one may borrow the idea from
Liu et al. (2016) which considers all candidate thresholds for a continuous marker when deriving
simultaneous confidence intervals.
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